CHICAGO—The present-day standard CHOP-rituximab regimen for all indolent lymphomas has been overturned according to German investigators reporting here to the annual meeting of the American Society of Clinical Oncology. Professor Mathias Rummel of Giessen University gave Peter Goodwin his latest findings which he recommends should change practice.
You may also like...
AACR In New Partnership For San Antonio Breast Cancer Symposium 14 Dec, 2007 Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer risk 6 Mar, 2014 How to Prevent Stomach and Esophageal Cancers? 26 Jan, 2008 Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease. 7 Mar, 2014
- Previous story Preparing for a healthy Olympics: lessons from the Hajj
- Next story Childhood Cancer Treatment: Model For Adult Therapy — ASCO President
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014